Literature DB >> 11320062

Genomic structure and transcriptional regulation of human Galbeta1,3GalNAc alpha2,3-sialyltransferase (hST3Gal I) gene.

A Taniguchi1, I Yoshikawa, K Matsumoto.   

Abstract

Previous studies have shown that hST3Gal I mRNA is overexpressed in colorectal cancer tissues and primary breast carcinoma compared with nonmalignant or benign tissue, suggesting that the transcriptional regulation of hST3Gal I gene is altered during malignant transformation. We report transcriptional regulation of the hST3Gal I gene in colon adenocarcinoma and leukemia cell lines. To determine the genomic structure of the 5'-untranslated region, we cloned and identified the 5'-untranslated region of hST3Gal I from a human genome library. The 5'-untranslated region was found to be divided into three exons, namely, exons Y, X, and C1. The transcription initiation sites map at -1035 bp from the translation initiation site. Our results indicate that the transcriptional regulation of hST3Gal I depends on the pI promoter that exists 5'-upstream of exon Y in these cell lines. The results of luciferase assay suggest that the nt -304 to -145 region is important for transcriptional activity of hST3Gal I gene in both cell lines. The nt -304 to -145 region contains two sequences similar to the Sp1 recognition elements (GC-box) and one USF binding site. The results of site-directed mutagenesis indicated that the Sp1 binding sites and USF binding site of the pI promoter are involved in the transcription of hST3Gal I mRNA. However, the triple mutant of these sites still exhibits about 50% transcriptional activity, suggesting that there are other transcription factors involved in the transcription of hST3Gal I mRNA. These results suggest that these factors may play a critical role in the up-regulation of the hST3Gal I gene during malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320062     DOI: 10.1093/glycob/11.3.241

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  6 in total

1.  Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer.

Authors:  Daisy Sproviero; Sylvain Julien; Brian Burford; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  J Biol Chem       Date:  2012-12-28       Impact factor: 5.157

2.  Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates.

Authors:  Tetsufumi Koike; Naoko Kimura; Keiko Miyazaki; Tomonori Yabuta; Kensuke Kumamoto; Seiichi Takenoshita; Jian Chen; Masanobu Kobayashi; Masuo Hosokawa; Akiyoshi Taniguchi; Tetsuhito Kojima; Nobuhiro Ishida; Masao Kawakita; Harumi Yamamoto; Hiromu Takematsu; Akemi Suzuki; Yasunori Kozutsumi; Reiji Kannagi; Reiji Kanangi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-12       Impact factor: 11.205

Review 3.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

4.  Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cells.

Authors:  Koji Hatano; Yasuhide Miyamoto; Masaki Mori; Keisuke Nimura; Yasutomo Nakai; Norio Nonomura; Yasufumi Kaneda
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

5.  Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity.

Authors:  Jaewoo Song; Cheng Xue; John S Preisser; Drake W Cramer; Katie L Houck; Guo Liu; Aaron R Folsom; David Couper; Fuli Yu; Jing-Fei Dong
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

Review 6.  Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?

Authors:  Silvia Pietrobono; Barbara Stecca
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.